Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update
Back to JobsOTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020 OTIPRIO ® co-promotion agreement completed with Glenmark Therapeutics OTIVIDEX™ Phase 3 trial in Ménière’s disease on track for results in first half of 2020 OTO-413 Phase 1/2 trial in hearing loss expected to
Apply Now